New prospects in the treatment of diabetes mellitus

Cardiovascular complications, a major cause for disability and morbidity in diabetes mellitus (DM), constitute the greatest threat of the diabetes epidemic. Glycemic stability within the therapeutic targets is a prerequisite to prevention of micro- and macrovascular complications of DM. Traditional...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minara Shamkhalovna Shamkhalova, Natalya Petrovna Trubitsyna, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2012
Materias:	diabetes mellitus incretins dpp-4 inhbitors linagliptin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/f1120e4cab23493e98a2446c72d6adc8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f1120e4cab23493e98a2446c72d6adc8
record_format	dspace
spelling	oai:doaj.org-article:f1120e4cab23493e98a2446c72d6adc82021-11-14T09:00:17ZNew prospects in the treatment of diabetes mellitus2072-03512072-037810.14341/2072-0351-5547https://doaj.org/article/f1120e4cab23493e98a2446c72d6adc82012-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5547https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Cardiovascular complications, a major cause for disability and morbidity in diabetes mellitus (DM), constitute the greatest threat of the diabetes epidemic. Glycemic stability within the therapeutic targets is a prerequisite to prevention of micro- and macrovascular complications of DM. Traditional therapies are aimed at cardinal defects determining development of type 2 diabetes mellitus (T2DM). Unfortunately even in combination they fail to deliver long-term glycemic control without stimulation of weight gain and increase in hypoglycemic risks with negative cardial, renal and hepatic impact. Preservation of beta-cell secretion capacity is also hardly attainable. Incretin-based therapy is a novel, actively developed approach that influences gut hormone physiology for better glycemic control. So far research efforts have yielded two classes of drugs: GLP-1 mimetics and DPP-4 inhibitors. Both are regarded nowadays for a number of important benefits, including beta-cell function improvement, adjusted to human physiology (i.e. stimulation of insulin secretion ?as needed? by the body, - hence low hypoglycemic risk). They also feature positive cardiovascular and body weight effects, thereby taking an important position in complex DM treatment.Minara Shamkhalovna ShamkhalovaNatalya Petrovna TrubitsynaMarina Vladimirovna ShestakovaEndocrinology Research Centrearticlediabetes mellitusincretinsdpp-4 inhbitorslinagliptinNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 15, Iss 4, Pp 109-114 (2012)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus incretins dpp-4 inhbitors linagliptin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus incretins dpp-4 inhbitors linagliptin Nutritional diseases. Deficiency diseases RC620-627 Minara Shamkhalovna Shamkhalova Natalya Petrovna Trubitsyna Marina Vladimirovna Shestakova New prospects in the treatment of diabetes mellitus
description	Cardiovascular complications, a major cause for disability and morbidity in diabetes mellitus (DM), constitute the greatest threat of the diabetes epidemic. Glycemic stability within the therapeutic targets is a prerequisite to prevention of micro- and macrovascular complications of DM. Traditional therapies are aimed at cardinal defects determining development of type 2 diabetes mellitus (T2DM). Unfortunately even in combination they fail to deliver long-term glycemic control without stimulation of weight gain and increase in hypoglycemic risks with negative cardial, renal and hepatic impact. Preservation of beta-cell secretion capacity is also hardly attainable. Incretin-based therapy is a novel, actively developed approach that influences gut hormone physiology for better glycemic control. So far research efforts have yielded two classes of drugs: GLP-1 mimetics and DPP-4 inhibitors. Both are regarded nowadays for a number of important benefits, including beta-cell function improvement, adjusted to human physiology (i.e. stimulation of insulin secretion ?as needed? by the body, - hence low hypoglycemic risk). They also feature positive cardiovascular and body weight effects, thereby taking an important position in complex DM treatment.
format	article
author	Minara Shamkhalovna Shamkhalova Natalya Petrovna Trubitsyna Marina Vladimirovna Shestakova
author_facet	Minara Shamkhalovna Shamkhalova Natalya Petrovna Trubitsyna Marina Vladimirovna Shestakova
author_sort	Minara Shamkhalovna Shamkhalova
title	New prospects in the treatment of diabetes mellitus
title_short	New prospects in the treatment of diabetes mellitus
title_full	New prospects in the treatment of diabetes mellitus
title_fullStr	New prospects in the treatment of diabetes mellitus
title_full_unstemmed	New prospects in the treatment of diabetes mellitus
title_sort	new prospects in the treatment of diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2012
url	https://doaj.org/article/f1120e4cab23493e98a2446c72d6adc8
work_keys_str_mv	AT minarashamkhalovnashamkhalova newprospectsinthetreatmentofdiabetesmellitus AT natalyapetrovnatrubitsyna newprospectsinthetreatmentofdiabetesmellitus AT marinavladimirovnashestakova newprospectsinthetreatmentofdiabetesmellitus
_version_	1718429623912497152

New prospects in the treatment of diabetes mellitus

Ejemplares similares